Lytix Biopharma Enters Clinical Collaboration with Iovance Biotherapeutics
Norwegian clinical-stage immunoncology company, Lytix Biopharma, has entered into a clinical collaboration with US-based Iovance Biotherapeutics.
Norwegian clinical-stage immunoncology company, Lytix Biopharma, has entered into a clinical collaboration with US-based Iovance Biotherapeutics, it was unveiled in a Nov. 10, 2019 press release.
The companies will collaborate to evaluate Lytix’s first-in-class oncolytic peptide, LTX-315, in combination with Iovance’s autologous ready to infuse T-cell therapy. Under the terms of the non-exclusive agreement, both companies will retain ownership of their own assets.
“We are very excited about the collaboration with Iovance, and the combination of our technologies can be a potential new approach to T cell therapy for cancers,” said Øystein Rekdal, CEO of Lytix Biopharma. “This agreement affirms that we remain committed to the further development of LTX-315 as a single agent and in combination with other therapies.”
Source: Lytix Biopharma
Benuvia Granted GMP Certification by Brazil National Health Surveillance Agency
March 14th 2025The certification allows Benuvia to produce pharmaceutical products for companies, either local to Brazil or international, that may be looking for compliant and high-quality production capabilities in the Brazilian pharmaceutical market.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
